Punjab Agricultural University patents a groundbreaking contraceptive bait for rodents, offering a humane and effective solution to protect crops and public health. Learn about this innovative pest control method.
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
New data shows semaglutide reduces major heart events by 20%, independent of weight loss. This breakthrough offers new hope for India's early-onset heart disease patients. Learn more.
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Discover the engineering marvel behind the tiny hole in every safety pin. From Walter Hunt's 1849 patent to modern uses, learn how this simple feature ensures durability and function.
Canada faces a surge in undocumented immigrants as work permits expire. With nearly half from India, expert Kanwar Seirah warns of social impact. Learn the critical details.
Tesla's global EV crown slips to China's BYD after a 9% delivery drop in 2025. Intense competition and expiring US tax credits hit sales. Can Musk's robotaxi and robotics pivot revive fortunes? Read the full analysis.
IIT Jodhpur achieves a milestone with 86 IPR filings in 2025, marking a 150% growth. The patents focus on affordable, sustainable tech for national priorities. Discover the institute's innovation drive.
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Mahatma Gandhi University patents an AI-powered drowsiness detection system developed by Prof. Pushpalatha K P & Vineetha Vijayan. It aims to slash road accidents via real-time alerts. Read more.
Food safety officials in Noida seized over 42 kg of Italian bread lacking expiry dates from a major sandwich chain. The crackdown is part of pre-New Year inspections across GB Nagar. Read for details.
Maharaja Sayajirao University's innovative 'Play Station for Toddlers' transforms into regular furniture. This modular, Montessori-inspired design promotes learning and safety. Read more about this patented innovation.
Indian stock markets consolidate amid F&O expiry and profit booking. Gold prices correct sharply by ₹5,000, Bitcoin slips ₹55,000. Experts share Nifty, Bank Nifty outlook and 8 stock picks for today.
Indian stock markets are set to end 2025 with double-digit gains despite a tough year. With two sessions left, experts predict consolidation and advise selective, value-focused investing for 2026.
Indian equity benchmarks opened flat on Thursday with low volumes as the year draws to a close. Analysts warn of potential volatility due to the monthly F&O expiry. Key sectors and stocks in focus.
Indian stock markets brace for a cautious final week of 2025 as FPIs and prop traders build significant bearish positions. Nifty expected to trade sideways with a bearish bias amid thin holiday volumes. Key details inside.
Kajol's journey from rejecting marital stereotypes to proposing expiry dates reflects a common evolution. A psychologist explains why our ideas of an ideal marriage change over time.
Vijay L. Bhambwani's analysis suggests monthly expiry and low year-end participation could restrict market upside. PSU banks and metals may see action, while bullion volatility persists. Trade light with stops.
Indian stock markets enter the year's final stretch with a focus on key economic data, auto sales, and global cues. Analysts expect range-bound trading with heightened volatility. Read more.
Sanskriti University in Mathura achieves All India Rank 6 for patent filings, reinforcing its commitment to research and innovation. Discover how it's shaping future innovators.
The Supreme Court has ruled that a driving licence is not valid after its expiry date unless renewed. Learn the legal implications and renewal process to avoid penalties.
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Hexaware Technologies seeks dismissal of a $500 million patent infringement suit filed by Natsoft, arguing the patents cover abstract ideas, not genuine inventions. The outcome could significantly impact the IT firm's finances.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.